加味一贯煎联合经导管肝动脉栓塞术治疗原发性肝癌42例临床研究  

A Clinical Observation on Supplemented Yiguan Brew Combined with Transcatheter Hepatic Arterial Chemo-Embolization for 42 Cases of Primary Liver Cancer

作　　者：卢义琼[1] 李华波[1] 

机构地区：[1]湖北民族学院附属民大医院

出　　处：《中医杂志》2013年第5期405-408,共4页Journal of Traditional Chinese Medicine

摘　　要：目的观察加味一贯煎联合经导管肝动脉栓塞术(TACE)治疗原发性肝癌的临床疗效。方法将中晚期原发性肝癌患者80例随机分为试验组42例和对照组38例,试验组采用加味一贯煎联合TACE治疗;对照组采用单纯TACE治疗。TACE后16周评价两组患者临床疗效,并于TACE前后检测患者血清甲胎蛋白(AFP)水平、肝功能、卡氏评分和血氧饱和度(SaO2)水平,同时观察患者不良反应。结果试验组总缓解率57.14%,对照组为47.37%,两组比较差异有统计学意义(P<0.05)。两组患者TACE后血清AFP水平较TACE前均下降(P<0.05);试验组TACE后第21、28天血清AFP水平显著低于对照组(P<0.05)。两组患者TACE后第3天肝功能各指标较TACE前均升高(P<0.05),试验组各指标在第28、84天均接近TACE前水平(P>0.05),对照组在第28、84天各项指标均明显高于TACE前水平(P<0.05),试验组患者TACE后肝功能各指标均明显低于同期对照组(P<0.05)。两组患者TACE后卡氏评分和SaO2水平均较TACE前提高(P<0.05),TACE后试验组卡氏评分明显高于对照组(P<0.05)。试验组不良反应发生率低于对照组(P<0.05)。结论加味一贯煎联合TACE治疗原发性肝癌临床疗效显著,能提高TACE的治疗效率并减少并发症及不良反应。Objective To observe the therapeutic effect of Supplemented Yiguan Brew （All-the-Way-Through Brew） combined with transcatheter hepatic arterial chemo-embolization （TACE） on primary liver cancer. Methods Eighty cases of advanced primary liver cancer were divided into the test group of 42 cases and control group of 38 cases according to the register number. Both groups were given TACE and Supplemented Yiguan Brew was added in the test group. The therapeutic effect was evaluated 16 weeks later. The serum alpha-fetoprotein （AFP） levels, liver function, Karnofsky scores, SaO2 levels and side effects in both groups were observed. Results The total remission rate in the test group and control group was 57.14% and 47.37 % respectively, with a significant difference between groups （P〈0.05）. The AFP levels in both groups were significantly decreased （P〈0.05）. The AFP levels in the test group were significantly lower than those in the control group on the 21st and 28th day after TACE （P〈0.05）. The liver function improved in both groups on the 3rd day after TACE （P〈0.05）. The indicators of liver function on the 28tb and 84th day were closed to those before TACE in the test group （P〈0.05）. The indicators of liver function on the 28th and 84th day were significantly higher than those before TACE in the control group （P〈0.05）. The indicators of liver function in the test group were significantly lower than those in the control group at the same time point after TACE （P〈0.05）. The Karnofsky scores and SaO2 levels were significantly increased in both groups after TACE （P〈0.05）. The Karnofsky score in the test group was significantly higher than that in the control group after TACE （P〈0.05）. The incidence of side effect in the test group was significantly lower than that in the control group （P〈0.05）. Conclusion Supplemented Yiguan Brew combined with TACE is effective for primary liver cancer with better efficacy, lower complications and less side effect.

关 键 词：原发性肝癌 一贯煎 经导管肝动脉栓塞术 甲胎蛋白 肝功能 

分 类 号：R735.7[医药卫生—肿瘤]